Author Interviews, Cancer Research, JAMA / 23.08.2019
Checkpoint Inhibitors’ Adverse Events Linked to Tumor Mutational Burden
MedicalResearch.com Interview with:
Prof. Dr. Lukas Flatz MD
Institute of Immunobiology
Kantonsspital St Gallen, St Gallen
Switzerland
MedicalResearch.com: What is the background for this study?
Response: Toxicity is an important limiting factor of treatment with checkpoint inhibitors. We aimed in investigating the relationship between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden by comparing large scale surveillance data of irAEs with the median tumor mutational burden across multiple cancer types.
(more…)